{
    "nct_id": "NCT03564665",
    "official_title": "A Randomized, Placebo Controlled, Single Blinded Trial of 400mg of Magnesium Glycinate BID Investigating the Body's Structure/Function Role of Hot Flashes.",
    "inclusion_criteria": "* Age: 25-85 years.\n* Women with a history of invasive breast cancer, DCIS, or LCIS\n* Creatine labs drawn within 90 days as part of Standard of Care.\n* Bothersome hot flashes (defined by their occurrence of two or more hot flashes a day and/or of sufficient severity to prompt the patient to seek therapeutic intervention).\n* Presence of hot flashes for >30 days prior to study entry.\n* Ability to complete questionnaire(s) by themselves or with assistance.\n* Ability to provide informed written consent.\n* Life expectancy ≥6 months.\n* Willing to work with the enrolling institution for follow-up (during the Active Monitoring Phase of the study).\n* ECOG Performance Status (PS) = 0, 1.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 25 Years\nMust have maximum age of 85 Years",
    "exclusion_criteria": "* Pregnancy (Assessed on Intake Questionnaire. Positive Answer exclusionary)\n* Any of the following current (≤4 weeks prior) or planned therapies:\n* Antineoplastic chemotherapy (anti-HER2 agents allowed)\n* Androgens\n* Estrogens (any delivery route)\n* Progestogens\n* Tamoxifen, raloxifene and aromatase inhibitors are allowed, but patient must have been on a constant dose for at least 28 days and must not be expected to stop the medication during the study period\n* SSRIs/SNRIs\n* Gabapentin\n* Clonidine\n* Oxybutinin\n* Stage IV or V renal disease or GFR<30 in the last 90 days",
    "miscellaneous_criteria": ""
}